So when you say the story here is uncompelling you are saying that owning the worldwide licensing rights for a Metformin eye drop formula to treat AMD when the main current treatment is a needle injection in the eye, is of no value. Given the size of the wet and dry AMD market to be in the multi billions with an ever aging population, some pharma company will see value in this and want to take it to market if trials prove effective. I disagree with your assessment but that is the beauty of a free market system. I think the demand will be there for this solution.
Wait so when they do the offering in the uplist we won’t be able to sell the stock for a couple days if we wanted to we basically won’t be able to do anything with a Stock for a couple days but the insiders will be able to sell their shares while we’re stuck?
News 
Market Data 
Discover 
AI
